Evaluating the Efficacy and Safety of Treatments for VMS During Adjuvant Endocrine Therapy

home / investigator-perspectives / evaluating-the-efficacy-and-safety-of-treatments-for-vms-during-adjuvant-endocrine-therapy

A panelist highlights that new nonhormonal treatments show promising, well-tolerated relief of persistent vasomotor symptoms (VMS) in patients with hormone receptor–positive breast cancer receiving endocrine therapy, improving quality of life and adherence while ongoing research addresses long-term safety and underserved populations.

© 2025 MJH Life Sciences

All rights reserved.